Literature DB >> 3033311

Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells.

Y Whang, M Silberklang, A Morgan, S Munshi, A B Lenny, R W Ellis, E Kieff.   

Abstract

The gene encoding the Epstein-Barr virus envelope glycoproteins gp350 and gp220 was inserted downstream of the cytomegalovirus immediate-early, Moloney murine leukemia virus, mouse mammary tumor virus, or varicella-zoster virus gpI promoters in vectors containing selectable markers. Host cell and recombinant vector systems were defined which enabled the isolation of rodent or primate cell clones which expressed gp350/220 in substantial quantities. Continued expression of gp350/220 required maintenance of cells under positive selection for linked markers and periodic cloning. gp350/220 expressed in various host cells varied slightly in electrophoretic mobility, probably reflecting differences in glycosylation. Insertion of a stop codon into the gp350/220 open reading frame, upstream of the putative membrane anchor sequence, resulted in efficient secretion of truncated gp350 and gp220 from rat pituitary (GH3) cells. gp350/220 expressed in mammalian cells is highly immunogenic and elicits virus-neutralizing antibodies when administered to mice.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3033311      PMCID： PMC254182          DOI： 10.1128/JVI.61.6.1796-1807.1987

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  58 in total

1.  Cross-neutralization of infectious mononucleosis and Burkitt lymphoma strains of Epstein-Barr virus with hyperimmune rabbit antisera.

Authors:  D Coope; L Heston; J Brandsma; G Miller
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

2.  Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study.

Authors:  G de-Thé; A Geser; N E Day; P M Tukei; E H Williams; D P Beri; P G Smith; A G Dean; G W Bronkamm; P Feorino; W Henle
Journal:  Nature       Date:  1978-08-24       Impact factor: 49.962

3.  Proteins of Epstein-Barr Virus. II. Electrophoretic analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide-containing components of enveloped virus.

Authors:  M Dolyniuk; E Wolff; E Kieff
Journal:  J Virol       Date:  1976-04       Impact factor: 5.103

4.  Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells.

Authors:  D A Thorley-Lawson
Journal:  Cell       Date:  1979-01       Impact factor: 41.582

Review 5.  Empirical predictions of protein conformation.

Authors:  P Y Chou; G D Fasman
Journal:  Annu Rev Biochem       Date:  1978       Impact factor: 23.643

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Synthesis and processing of the three major envelope glycoproteins of Epstein-Barr virus.

Authors:  C M Edson; D A Thorley-Lawson
Journal:  J Virol       Date:  1983-05       Impact factor: 5.103

8.  Glycosylation pathways of two major Epstein-Barr virus membrane antigens.

Authors:  B C Strnad; M R Adams; H Rabin
Journal:  Virology       Date:  1983-05       Impact factor: 3.616

9.  Patterns of amino acids near signal-sequence cleavage sites.

Authors:  G von Heijne
Journal:  Eur J Biochem       Date:  1983-06-01

10.  DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells.

Authors:  M Wigler; A Pellicer; S Silverstein; R Axel; G Urlaub; L Chasin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205
View more
  17 in total

Review 1.  Control of viral disease: the development of Epstein-Barr virus vaccines.

Authors:  A J Morgan
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Subcellular distribution and life cycle of Epstein-Barr virus in keratinocytes of oral hairy leukoplakia.

Authors:  J P Rabanus; D Greenspan; V Petersen; U Leser; H Wolf; J S Greenspan
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

3.  Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.

Authors:  M D Moore; M J Cannon; A Sewall; M Finlayson; M Okimoto; G R Nemerow
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

4.  Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.

Authors:  M Khyatti; P C Patel; I Stefanescu; J Menezes
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

5.  Identification and characterization of Kaposi's sarcoma-associated herpesvirus K8.1 virion glycoprotein.

Authors:  M Li; J MacKey; S C Czajak; R C Desrosiers; A A Lackner; J U Jung
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

6.  Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes.

Authors:  J Tanner; Y Whang; J Sample; A Sears; E Kieff
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

7.  Induction of antibodies to the Epstein-Barr virus glycoprotein gp85 with a synthetic peptide corresponding to a sequence in the BXLF2 open reading frame.

Authors:  D E Oba; L M Hutt-Fletcher
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

8.  Glycoprotein 110, the Epstein-Barr virus homolog of herpes simplex virus glycoprotein B, is essential for Epstein-Barr virus replication in vivo.

Authors:  R E Herrold; A Marchini; S Fruehling; R Longnecker
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

9.  Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones.

Authors:  L E Wallace; J Wright; D O Ulaeto; A J Morgan; A B Rickinson
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

10.  Papillomavirus E7 protein binding to the retinoblastoma protein is not required for viral induction of warts.

Authors:  D Defeo-Jones; G A Vuocolo; K M Haskell; M G Hanobik; D M Kiefer; E M McAvoy; M Ivey-Hoyle; J L Brandsma; A Oliff; R E Jones
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.